CoChat
Sign Up
Cited by 39Liver Diseases and ImmunityIgG4-Related and Inflammatory DiseasesDrug-Induced Hepatotoxicity and Protection

B-Cell Activating Factor Belonging to the Tumor Necrosis Factor Family and Interferon-γ-Inducible Protein-10 in Autoimmune Hepatitis

Open access
Nishikawa, Hiroki, Enomoto, Hirayuki, Iwata, Yoshinori, Kishino, Kyohei, Shimono, Yoshihiro, Hasegawa, Kunihiro, Nakano, Chikage, Takata, Ryo +9 more·2016·Medicine
DOI 10.1097/md.0000000000003194PMC PMC4998411
Open this paper in CoChat — free account

Abstract

The aims of the present study were to examine the relationship between serum B-cell activating factor belonging to the tumor necrosis factor family (BAFF) levels and serum interferon-γ-inducible protein-10 (IP-10) levels in patients with autoimmune hepatitis (AIH).A total of 80 corticosteroid therapy naive AIH patients were analyzed in this analysis. First, we examined the relationship between pretreatment serum BAFF and IP-10 levels and liver histological findings. Next, we investigated the relationship of pretreatment serum BAFF and IP-10 levels and aspartate aminotransferase value (AST), alanine aminotransferase value, and serum Immunoglobulin G (IgG) level as serum liver inflammation markers.Our study included 14 men and 66 women with the median (range) age of 64 (21-83) years. The serum BAFF levels ranged from 122.5 to 7696.0 pg/mL (median value, 1417.8 pg/mL), whereas the serum IP-10 levels ranged from 142.0 to 4198.7 pg/mL (median value, 640.1 pg/mL). The serum BAFF levels were significantly stratified in each 2 liver inflammation stage. Similarly, the serum IP-10 levels were significantly stratified in each 2 liver inflammation stage. Among 3 serum inflammation markers, AST value had the highest rs value in terms of the relationship with BAFF level (rs = 0.511, P < 0.001) and IP-10 level (rs = 0.626, P < 0.001). In addition, the serum BAFF level significantly correlated with serum IP-10 level (rs = 0.561, P < 0.001). In patients without advanced fibrosis (F3 or more), the serum BAFF level significantly correlated with serum IP-10 level (rs = 0.658, P < 0.001), whereas in patients with advanced fibrosis, the serum BAFF level significantly correlated with serum IP-10 level (rs = 0.542, P < 0.001).In conclusion, both BAFF and IP-10 are useful for predicting the degree of liver inflammation activity in AIH. BAFF and IP-10 may have the common clinical implication for liver inflammation activity for AIH patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/md.0000000000003194

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In humans, the level of CXCL10 is tightly correlated with B cell activating factor (BAFF).

    “in human, the level of CXCL10 is tightly correlated with B cell activating factor (BAFF)(388).”

    From The liver as a central "hub" of the immune system: pathophysiological implications (2025) · cites this paper as [388]

    The Results (Relationship Between BAFF level and IP-10 Level; page not available) report a significant serum BAFF–IP-10/CXCL10 correlation (rs = 0.561, P < 0.001). However, the study concerns patients with autoimmune hepatitis, not humans generally, and “tightly correlated” overstates the reported moderate correlation. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

  • Roles for chemokines in liver disease

    Marra, F., & Tacke, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.043 · Cited by 829 · cited 1× · see citing works

    “Inflammation in the liver is also regulated by chemokines, which regulate the activities and migration of Kupffer cells, hepatocytes, endothelial cells, hepatic stellate cells, and circulating immune cells.(20) Interferon-g-inducible protein-10 (IP-10) is a T-cell-specific CXC chemokine of 77 amino acids in its mature…”
    Background

Flagged first, then by citations

Research works printed but not linked: 33

  1. [1]Manns MP Lohse AW Vergani D Autoimmune hepatitis—Update 2015. J Hepatol 2015; 62: S100– S111. 25920079
  2. [2]Abe M Mashiba T Zeniya M Autoimmune Hepatitis Study Group–Subgroup of the Intractable Hepato-Biliary Disease Study Group in Japan. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol 2011; 46: 1136– 1141. 21597932
  3. [3]Krawitt EL Autoimmune hepatitis. N Engl J Med 2006; 354: 54– 66. 16394302
  4. [4]Yang F Wang Q Jia J Autoimmune hepatitis: East meets West. J Gastroenterol Hepatol 2015; 30: 1230– 1236. 25765710
  5. [5]Onji M Zeniya M Yamamoto K Autoimmune hepatitis: diagnosis and treatment guide in Japan, 2013. Hepatol Res 2014; 44: 368– 370. 25989393
  6. [6]Carbone M Neuberger JM Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol 2014; 60: 210– 223. 24084655
  7. [7]Schneider P MacKay F Steiner V BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747– 1756. 10359578 PMC2193079
  8. [8]Yang S Li JY Xu W Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma. Crit Rev Oncol Hematol 2014; 91: 113– 122. 24629840
  9. [9]Zhao LD Li Y Smith MF Jr Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus 2010; 19: 1534– 1549. 20974656
  10. [10]Matsushita T Hasegawa M Yanaba K Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006; 54: 192– 201. 16385515
  11. [11]Migita K Ilyassova B Kovzel EF Serum BAFF and APRIL levels in patients with PBC. Clin Immunol 2010; 134: 217– 225. 19840904
  12. [12]Migita K Abiru S Maeda Y Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol 2007; 68: 586– 591. 17584580
  13. [13]Toubi E Gordon S Kessel A Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 2006; 27: 134– 139. 17029886
  14. [14]Sène D Limal N Ghillani-Dalbin P Hepatitis C virus-associated B-cell proliferation—the role of serum B lymphocyte stimulator (BLyS/BAFF). Rheumatology (Oxford) 2007; 46: 65– 69. 16782735
  15. [15]Mackay IR Groom J Mackay CR Levels of BAFF in serum in primary biliary cirrhosis and autoimmune diabetes. Autoimmunity 2002; 35: 551– 553. 12765482
  16. [16]Yang C Li N Wang Y Serum levels of B-cell activating factor in chronic hepatitis B virus infection: association with clinical diseases. J Interferon Cytokine Res 2014; 34: 787– 794. 24811691 PMC4186800
  17. [17]Hengeveld PJ Kersten MJ B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? Blood Cancer J 2015; 5: e282. 25723853 PMC4349256
  18. [18]Ferrer G Bosch R Hodgson K B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL. Br J Haematol 2014; 164: 570– 578. 24245956
  19. [19]Rihacek M Bienertova-Vasku J Valik D B-Cell activating factor as a cancer biomarker and its implications in cancer-related cachexia. Biomed Res Int 2015; 792187. 26339644 PMC4538579
  20. [21]Grebely J Feld JJ Applegate T Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology 2013; 57: 2124– 2134. 23325615 PMC3663887
  21. [22]Diago M Castellano G García-Samaniego J Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 2006; 55: 374– 379. 16150856 PMC1856069
  22. [23]Harvey CE Post JJ Palladinetti P Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003; 74: 360– 369. 12949239
  23. [24]Zeremski M Petrovic LM Chiriboga L Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 1440– 1450. 18798334 PMC2579317
  24. [25]Nishioji K Okanoue T Itoh Y Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin Exp Immunol 2001; 123: 271– 279. 11207658 PMC1905987
  25. [26]Czaja AJ Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets. Aliment Pharmacol Ther 2014; 40: 261– 279. 24890045
  26. [27]Alvarez F Berg PA Bianchi FB International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929– 938. 10580593
  27. [28]Mahler M Meroni PL Bossuyt X Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res 2014; 315179. 24868563 PMC4020446
  28. [29]Nishikawa H Enomoto H Nasu A Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy. Hepatol Res 2014; 44: E397– E407. 24628684
  29. [30]Nishikawa H Enomoto H Iwata Y Impact of serum Wisteria floribunda agglutinin positive Mac-2-binding protein and serum interferon-γ-inducible protein-10 in primary biliary cirrhosis. Hepatol Res 2015; doi:10.1111/hepr.12595. 26418076 · DOI
  30. [31]Sutherland AP Ng LG Fletcher CA BAFF augments certain Th1-associated inflammatory responses. J Immunol 2005; 174: 5537– 5544. 15843552
  31. [32]Heim MH Thimme R Innate and adaptive immune responses in HCV infections. J Hepatol 2014; 61 (1 Suppl): S14– 25. 25443342
  32. [33]Seki E Schwabe RF Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology 2015; 61: 1066– 1079. 25066777 PMC4306641
  33. [34]Tian Z Chen Y Gao B Natural killer cells in liver disease. Hepatology 2013; 57: 1654– 1662. 23111952 PMC3573257

Cited by

Sorted by citations

Authors
Nishikawa, H., Enomoto, H., Iwata, Y., Kishino, K., Shimono, Y., Hasegawa, K., Nakano, C., Takata, R., Nishimura, T., Yoh, K., Ishii, A., Aizawa, N., Sakai, Y., Ikeda, N., Takashima, T., Iijima, H., & Nishiguchi, S.
Affiliations
Hyogo Medical University (JP)
Corresponding author
Enomoto, Hirayuki
ORCID
Venue
Medicine
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2016-03
Volume
95
Issue
12
Pages
e3194
ISSN
0025-7974 (ISSN-L)
DOI
10.1097/md.0000000000003194
PMC
PMC4998411
OpenAlex
W2306365180
Cited by
39
References
1
Citations by year
2026: 2 · 2025: 5 · 2024: 2 · 2023: 3 · 2022: 8 · 2021: 5 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 2
FWCI
2.41
Type
journal article
Language
en
Open access
Licence
cc-by-nd
Locations
  • Medicine (publishedVersion, cc-by-nd)
  • PubMed Central (publishedVersion, cc-by-nd)
  • PubMed (publishedVersion)
Funders
  • Dainippon Sumitomo Pharma
  • Chugai Pharmaceutical
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
autoimmune hepatitis, B-cell activating factor, BAFF, CXCL10, liver inflammation, liver fibrosis, serum biomarkers, aspartate aminotransferase, alanine aminotransferase, IgG, disease activity prediction, prognostic factors
MeSH terms
Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Biomarkers, Hepatitis, Autoimmune, Tumor Necrosis Factors, B-Cell Activating Factor, Chemokine CXCL10, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review